Cian Healthcare Ltd

AI
Cian Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Cian Healthcare Ltd

₹ 16.2 4.97%
15 Sep - close price
cian.co BSE - SME: 542678
About

Cian Healthcare Ltd is a BSE-SME listed pharmaceutical-formulations manufacturer
with own /franchise brands, third-party manufacturing, institutional/government
supply and exports. It makes tablets, capsules, soft-gels, liquid orals, ointments/creams, sachets and cosmetics across gynaecology, haematinic, cardio-diabetic, orthopaedic, paediatric, derma-cosmetic, antibiotic, CNS, vitamins and nutrients. The company exited CIRP under new promoter control in FY26[1]

Key Points

Business model, customers & mix:
The parent sells through contract manufacturing, government/institutional tenders, exports and own-brand/franchise distribution. FY25 channel sales were ₹34.25 crore: third party ₹24.64 crore/72%, direct exports ₹4.53 crore/13%, merchant exports ₹2.48 crore/7%, government ₹1.67 crore/5% and other ₹0.93 crore/3%.[1][2]

Website BSE
  • Market Cap ₹ 40.6 Cr.
  • Current Price ₹ 16.2
  • High / Low ₹ 16.2 / 4.18
  • Stock P/E
  • Book Value ₹ 3.42
  • Dividend Yield 0.00 %
  • ROCE -15.5 %
  • ROE -49.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Promoter holding has increased by 67.9% over last quarter.

Cons

  • Stock is trading at 4.76 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -17.4% over past five years.
  • Company has a low return on equity of -18.6% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 163 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Mar 2026
29 28 39 35 47 31 38 31 33 62 19 12 17
26 23 34 28 44 30 32 24 28 51 20 17 20
Operating Profit 3 4 5 7 3 1 5 7 4 11 -1 -5 -3
OPM % 10% 15% 13% 20% 7% 2.9% 14% 22% 14% 18% -8% -44% -18%
0 1 -0 0 0 0 1 0 0 0 -12 0 -13
Interest 4 4 4 4 3 3 3 3 3 6 2 1 0
Depreciation 2 3 2 1 2 2 3 3 3 5 2 2 2
Profit before tax -2 -2 -1 2 -2 -4 0 2 -1 0 -18 -8 -18
Tax % 0% 17% 23% 28% 7% -13% -167% 14% 37% -400% 0% -0% 0%
-2 -2 -1 1 -2 -4 0 2 -1 0 -18 -8 -18
EPS in Rs -0.86 -0.75 -0.46 0.48 -0.72 -1.54 0.19 0.62 -0.59 0.10 -7.30 -3.09 -7.19
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
57 74 78 69 62 31 28
50 62 74 56 51 37 35
Operating Profit 7 12 4 13 11 -7 -7
OPM % 13% 16% 6% 19% 18% -21% -24%
1 0 0 1 0 -12 -12
Interest 7 8 7 6 6 3 0
Depreciation 4 3 4 5 5 4 4
Profit before tax -4 1 -6 2 0 -26 -23
Tax % 7% 91% -8% -2% -1,600% -0% 0%
-4 0 -6 2 1 -26 -23
EPS in Rs -1.62 0.02 -2.21 0.81 0.34 -10.39 -9.32
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -17%
3 Years: -26%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 27%
Stock Price CAGR
10 Years: %
5 Years: -6%
3 Years: -13%
1 Year: 296%
Return on Equity
10 Years: %
5 Years: -11%
3 Years: -19%
Last Year: -49%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 23 23 25 25 25 25 25
Reserves 35 35 30 32 33 7 -16
73 71 63 61 56 55 29
25 28 47 42 47 69 24
Total Liabilities 157 157 166 160 161 156 62
39 37 50 45 39 35 32
CWIP 25 26 13 14 15 15 6
Investments 5 5 5 5 5 5 0
87 90 98 97 102 101 23
Total Assets 157 157 166 160 161 156 62

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-7 6 9 5 12 21 21
-27 3 1 3 -1 -0 13
36 -10 -11 -7 -10 -4 -50
Net Cash Flow 1 -1 -1 -0 -0 17 -17
Free Cash Flow -26 4 4 4 11 20 29
CFO/OP -99% 49% 197% 37% 106% -315% -296%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 128 94 125 140 121 206 163
Inventory Days 214 277 300 400 486 420 82
Days Payable 176 186 270 296 371 671 219
Cash Conversion Cycle 166 185 155 244 236 -45 26
Working Capital Days 15 16 38 41 26 -729 -96
ROCE % 7% 0% 7% 5% -11% -16%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Permanent Employees on Rolls
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Export Revenue Share
% ・Standalone data
Production Volume
units ・Standalone data
Third Party / Contract Manufacturing Share of Revenue
% ・Standalone data
Number of Brands Marketed
count ・Standalone data
Number of Manufacturing Facilities
count
Number of Molecules Registered
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Sep 2025Mar 2026
66.26% 66.26% 66.26% 66.26% 51.85% 49.62% 27.10% 27.10% 27.11% 27.11% 27.11% 95.00%
0.00% 0.00% 0.00% 0.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
33.74% 33.74% 33.75% 32.96% 48.16% 50.39% 72.90% 72.90% 72.90% 72.89% 72.89% 5.00%
No. of Shareholders 3963924244184546728808311,0881,5011,6621,683

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings